CBD Life Sciences Subsidiary LBC Bioscience Launches CBD Based Pain Relief Products for Pets


SCOTTSDALE, ARIZONA, Feb. 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CBD Life Sciences Inc. (OTC:OCSYD) is pleased to announce that its wholly owned subsidiary, LBC Bioscience Inc, has launched a line of CBD based pain relief products for the domesticated pet market.

As evidence continues to surface over the benefits of CBD for humans, more people are turning their attention to what it can do for their pets. CBD for domesticated animals, most notably cats and dogs, is gaining considerable attention from consumers. With pet owners spending more than $30 billion a year on supplements and other types of treatments, LBC Bioscience is well positioned to offer a complete line of products. Many veterinarians have found that CBD can help older pets with joint pain. It is also useful in treating acute ailments like sprains and strains, torn ligaments, bone breaks, and even during post-operative care to reduce swelling, pain, and stiffness.

LBC Bioscience offers the following pain relief products for the domesticated animal market:

Pain Relief Cream

CBD based pain relief topical cream for cats, dogs, horses, and all other domesticated animals is an ultra-strength, fast acting, deep penetrating, soothing formula. Made in the USA, organic, THC free & non-GMO, this cream helps provide pain relief from sore aching joints and muscles, soothes skin irritations related to insect bites, helps relieve arthritis, acute strains or torn ligaments. Apply to the affected area and massage until absorbed into skin. Repeat as necessary.

Oral Drop 

CBD oral drop that is formulated to help reduce pain and discomfort that comes along with old age or injury. Made in the USA, organic, THC free & non-GMO, this spray helps provide relief from arthritis, sore and aching joints and muscles. Drop into mouth and repeat as necessary.

About CBD Life Sciences Inc.

CBD Life Sciences Inc. is a publicly traded company having its common shares quoted on the OTC Markets under the symbol ‘OCSYD’. The Company’s main focus is to identify, evaluate and acquire undervalued opportunities with the objective of increasing shareholder value. The acquisition of LBC Bioscience Inc. is the first in the CBD space and the company is actively searching for additional opportunities within this emerging sector.

About LBC Bioscience Inc.  

LBC Bioscience Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. LBC is developing and marketing a line of cannabidiol based organic products such as hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions, supplements, edibles, and a full line of pet products.  In addition, LBC is in the process of developing an anti-aging skin product line. LBC’s products can be viewed and purchased on the company’s website at www.lbcbioscienceinc.com.

Contact Information

Investor Relations
Ten Associates LLC

11529 N. 120th St.

Scottsdale, Arizona

85259 USA

Telephone: 480-326-8577

Contact: Thomas E. Nelson

Email: tenassociates33@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Optium Cyber Systems, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.